Development of positron emission tomography imaging by 64Cu-labeled Fab for detecting ERC/mesothelin in a mesothelioma mouse model

Nuclear Medicine Communications

Volumn 31, Issue 5, 2010, Pages 380-388

  Yoshida, Chisato ^a,b   Sogawa, Chizuru ^a   Tsuji, Atsushi B ^a   Sudo, Hitomi ^a,c   Sugyo, Aya ^a   Uehara, Tomoya ^b   Hino, Okio ^c   Yoshii, Yukie ^d   Fujibayashi, Yasuhisa ^d   Fukumura, Toshimitsu ^a   Koizumi, Mitsuru ^a   Arano, Yasushi ^b   Saga, Tsuneo ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF FUKUI   (Japan)

Author keywords

Antibody; ERC mesothelin; Mesothelioma; Positron emission tomography

Indexed keywords

COPPER 64; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; INDIUM 111; IODINE 125; MESOTHELIN; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING ASSAY; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; COMPETITIVE INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALIGNANT MESOTHELIOMA; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY;

ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COPPER RADIOISOTOPES; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INDIUM RADIOISOTOPES; IODINE RADIOISOTOPES; MEMBRANE GLYCOPROTEINS; MESOTHELIOMA; MICE; MICE, INBRED BALB C; POSITRON-EMISSION TOMOGRAPHY;

EID: 77951059310     PISSN: 01433636     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328336733d     Document Type: Article

References (21)

1. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005; 353:1591-1603.
2. Tsiouris A,Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. Nat Clin Pract Oncol 2007; 4:344-352. (Pubitemid 46864308)
3. Kanazawa N, Ioka A, Tsukuma H, Ajiki W, Oshima A. Incidence and survival of mesothelioma in Osaka, Japan. Jpn J Clin Oncol 2006; 36:254-257. (Pubitemid 43997326)
4. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br J Cancer 1999; 79:666-672. (Pubitemid 29046253)
5. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117:54-63. Discussion-5.
6. Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. Pathol Int 2006; 56:649-654. (Pubitemid 44570013)
7. Ishikawa K, Segawa T, Hagiwara Y, Maeda M, Abe M, Hino O. Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers. Pathol Int 2009; 59:161-166.
8. Shiomi K, Hagiwara Y, Sonoue K, Segawa T, Miyashita K, Maeda M, et al. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/ mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res 2008; 14:1431-1437. (Pubitemid 351413926)
9. Hassan R, Wu C, Brechbiel MW, Margulies I, Kreitman RJ, Pastan I. 111Indium-labeled monoclonal antibody K1: biodistribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. Int J Cancer 1999; 80:559-563. (Pubitemid 29047521)
10. Sato N, Hassan R, Axworthy DB, Wong KJ, Yu S, Theodore LJ, et al. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. J Nucl Med 2005; 46:1201-1209. (Pubitemid 43741083)
11. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 2009; 15:5274-5279.
12. Tsuji AB, Sogawa C, Sugyo A, Sudo H, Toyohara J, Koizumi M, et al. Comparison of conventional and novel PET tracers for imaging mesothelioma in nude mice with subcutaneous and intrapleural xenografts. Nucl Med Biol 2009; 36:379-388.
13. McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS, et al. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol 1997; 24:35-43.
14. Saga T, Sakahara H, Yao Z, Nakamoto Y, Sato N, Hattori N, et al. Detection of altered adhesion molecule expression in experimental tumors by a radiolabeled monoclonal antibody. Jpn J Cancer Res 1997; 88:1171-1180. (Pubitemid 28048264)
15. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72:77-89. (Pubitemid 14091996)
16. Saga T, Endo K, Akiyama T, Sakahara H, Koizumi M, Watanabe Y, et al. Scintigraphic detection of overexpressed c-erbB-2 protooncogene products by a class-switched murine anti-c-erbB-2 protein monoclonal antibody. Cancer Res 1991; 51:990-994.
17. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005; 46 (Suppl 1): 115S-127S. (Pubitemid 47619027)
18. Arano Y, Fujioka Y, Akizawa H, Ono M, Uehara T,Wakisaka K, et al. Chemical design of radiolabeled antibody fragments for low renal radioactivity levels. Cancer Res 1999; 59:128-134. (Pubitemid 29062968)
19. Becker WS, Behr TM, Cumme F, Rossler W, Wendler J, Kern PM, et al. 67Ga citrate versus 99mTc-labeled LL2-Fab' (anti-CD22) fragments in the staging of B-cell non-Hodgkin's lymphoma. Cancer Res 1995; 55:5771s-5773s.
20. Uehara T, Koike M, Nakata H, Hanaoka H, Iida Y, Hashimoto K, et al. Design, synthesis, and evaluation of [188Re]organorhenium-labeled antibody fragments with renal enzyme-cleavable linkage for low renal radioactivity levels. Bioconjug Chem 2007; 18:190-198. (Pubitemid 46146010)
21. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005; 23:1126-1136. (Pubitemid 41486394)